Photo from ESMO/LinkedIn
Jun 28, 2024, 10:52
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
ESMO shared a post on LinkedIn:
“ESMOGI24: Colorectal Cancer (CRC) can be classified into two groups based on its ability to repair DNA microsatellite damage.
Tumours that are mismatch repair-deficient and have high levels of microsatellite instability (MSI) have shown remarkable responses to immunotherapy, particularly checkpoint inhibitors.
On the other hand, tumours that are mismatch repair-proficient and microsatellite stable (MSS) have a lower mutational burden and have historically been less responsive to immunotherapeutic strategies.
To learn more about overcoming barriers to immunotherapy for microsatellite stable Colorectal Cancer, read the Opinion by Myriam Chalabi in the ESMO Daily Reporter.”
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20